The North America APAC In Situ Hybridization market is experiencing robust growth, driven by technological innovations and the rising adoption of advanced diagnostics in healthcare and research applications across the regions. Market size was valued at USD 440 million in 2025 and is projected to reach USD 1,120 million by 2035, expanding at a CAGR of 8.9% from 2024 to 2035.
The economic impact of tariffs on "North America APAC In Situ Hybridization Market".
Market Growth Drivers
Technological Advancements in ISH Platforms: Continuous progress in in situ hybridization methods, such as the integration of automation and multiplexing, is significantly enhancing efficiency and reproducibility in diagnostics. For example, Agilent Technologies recently introduced its latest automated ISH system, which enables simultaneous detection of multiple markers and reduces the turnaround time for clinical laboratories in North America and APAC.
Increasing Incidence of Cancer and Genetic Disorders: The surge in prevalence of cancer and rare genetic diseases in both North America and APAC is fuelling the demand for sensitive and accurate diagnostic approaches like ISH. Roche expanded its ISH product portfolio to cater to oncology research in early 2024, enabling oncologists and pathologists to improve early detection and personalized treatment decisions.
Market Trends
Growing Adoption of Companion Diagnostics: There is a notable trend towards leveraging ISH technologies for companion diagnostics, particularly in personalized medicine. Companies such as Thermo Fisher Scientific are collaborating with pharmaceutical firms to develop ISH-based assays that guide targeted therapy decisions—especially in oncology—across the North America and APAC regions.
Expansion of Digital Pathology Solutions: The combination of ISH with digital pathology platforms is gaining traction, facilitating remote analysis and improving workflow efficiency. In May 2024, Leica Biosystems announced integration of their digital pathology software with ISH assay output, streamlining data sharing between laboratories and supporting telemedicine initiatives.
Market Opportunities
Emergence of AI-Driven Image Analysis: The use of artificial intelligence for analyzing ISH assay results offers a significant opportunity to increase diagnostic accuracy and throughput, particularly for large-scale cancer screening programs. Companies like NanoString Technologies are pioneering AI algorithms to interpret complex ISH data in APAC hospitals.
Expansion in Emerging Markets: Untapped healthcare markets in Southeast Asia present lucrative growth opportunities for ISH technology providers. In 2024, Advanced Cell Diagnostics expanded its distribution network in India and Southeast Asia, aiming to penetrate new customer segments and research institutes.
North America APAC In Situ Hybridization Market Revenue (USD Million), 2020-2035
The market revenue chart illustrates a strong and steady growth trajectory from 2020's USD 250 million to USD 1,120 million by 2035. Early years (2020-2023) display moderate growth, driven by gradual adoption in clinical diagnostics. From 2024 onward, adoption in research and companion diagnostics, combined with technological advances, propels a steeper increase. By 2025, the market reaches USD 440 million and almost triples by 2035 amid increased cancer diagnostics and expansion into emerging regional markets. This upward trend highlights the dynamic evolution in both North America and APAC, positioning ISH technologies as a cornerstone in molecular pathology.
Market Share by Region, 2025 (%)
The 2025 pie chart data shows North America leads with 38% of the revenue, emphasizing the region's advanced diagnostics infrastructure and high research investment. East Asia (China, Japan, S. Korea) accounts for 29%, driven by increasing R&D funding. Southeast Asia holds 12%, experiencing the market’s highest regional growth rate following public health initiatives. Oceania (Australia & NZ) represents 10% share due to rising adoption in research and diagnostics, while South Asia (India, Pakistan, etc.) covers 11%, reflecting expanding healthcare access and international collaborations.
Recent Developments (Past 6 Months)
In March 2024, Roche Diagnostics launched a new RNA ISH assay kit in North America and APAC, designed for multiplexed biomarker detection in lung and breast cancer research, accelerating clinical decision-making in leading cancer hospitals.
Advanced Cell Diagnostics signed a strategic partnership in April 2024 with Apollo Hospitals (India) to implement its RNAscope ISH platform for rare disease diagnosis, establishing one of the largest ISH reference networks in Southeast Asia.
In May 2024, Leica Biosystems announced regulatory approval of its combined digital pathology and ISH workflow software in Japan and South Korea, allowing remote pathologists to interpret ISH results, thereby expanding telepathology capabilities across the APAC region.
Press Releases